Truveta
Truveta is a health tech company providing regulatory-grade EHR data for research, including clinical notes, images, and claims data.
Secondary Market Price
How Truveta Measures Up
To help you manage your Truveta equity, Prospect has run the company through our machine learning model.
Prospect Rating
--
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series C
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Truveta's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Truveta Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Truveta's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Truveta is a health technology company, founded in 2020, that provides a platform for analyzing electronic health record (EHR) data. The company was established as a collective of United States health systems with the stated mission of "Saving Lives with Data." It aggregates and de-identifies EHR data from its partners, which include over 30 health systems representing 800 hospitals and 20,000 clinics across all 50 states. This dataset, which covers approximately 17% of daily clinical care in the U.S., combines EHR information with claims, images, clinician notes, and social determinants of health data. The platform is used by life science, public health, and academic research organizations to study patient care and develop new therapies. The company was co-founded by Terry Myerson, Jay Nanduri, and Lisa Gurry and is headquartered in Bellevue, Washington.
Recent company activities provide insight into its current focus. Truveta launched "Truveta Live Link," a service that allows organizations to connect their own proprietary data from devices or therapies with Truveta's real-world clinical data. In a case study with Dexcom, this capability was used to link data from continuous glucose monitors with the EHR data of over 200,000 patients to study the progression of chronic kidney disease. The company also leads the Truveta Genome Project, an initiative to build a large-scale, diverse genomics database for research. In addition to product development, Truveta has recently published research on topics such as childhood vaccination rates and presented findings on stroke outcomes in collaboration with the pharmaceutical company Bayer.
- Regeneron Pharmaceuticals
- Illumina
- Providence Health & Services
- Trinity Health
- Northwell Health
- Advocate Health
- CommonSpirit Health
- Henry Ford Health
- Baylor Scott & White Health
- MedStar Health
- Texas Health Resources
- AdventHealth
- Baptist Health
- Bon Secours Mercy Health
- Hawaii Pacific Health
- Memorial Hermann Health System
- Novant Health
- Sentara Healthcare
- Tenet Healthcare Corporation
- Co-Founder, CEO Terry Myerson
- Co-Founder, CTO Jay Nanduri
- Co-Founder, CPO Ryan Ahern
- Co-Founder, CCO Lisa Gurry
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Truveta worth joining?
Evaluating an offer from a private company like Truveta requires assessing the potential value of its equity compensation. Tools like Prospect can help you make a more informed decision by providing data-driven models to project the future value of your shares.
What should I do with my Truveta stock?
Managing private stock involves complex decisions about when to exercise options or sell shares to maximize your returns and minimize taxes. Platforms like Prospect offer personalized strategies and scenario modeling to help you navigate these choices effectively.
Can you sell Truveta stock?
Selling stock in a private company like Truveta is typically restricted and only possible during specific events like tender offers or secondary market transactions. Prospect provides tender offer tools and market data to help you identify and take advantage of these liquidity opportunities.
How can I find the value of my Truveta stock?
The value of private stock is often determined by its 409A valuation, but its future potential can be projected using more advanced methods. Prospect uses predictive models trained on VC data to help you forecast the potential future value of your Truveta equity.
What is Truveta's equity worth?
The precise worth of private company equity fluctuates and is not publicly available, but you can estimate its potential value. Tools from Prospect can help you model different scenarios and project your equity's future worth based on data used by professional investors.
What is Truveta's stock ticker symbol?
As a private company, Truveta is not traded on a public stock exchange and therefore does not have a stock ticker symbol. Ticker symbols are assigned only when a company undergoes an Initial Public Offering (IPO).
Can I buy or sell Truveta stock?
Buying or selling stock in a private company like Truveta is generally limited to specific liquidity events, such as company-approved tender offers or secondary market sales. Platforms like Prospect provide tools and analysis to help you make optimal decisions during these opportunities.
What is the criteria to buy or invest in Truveta stock?
Investing in a private company like Truveta typically requires being an accredited investor or an employee receiving equity compensation. To evaluate the investment, you can use tools like Prospect, which uses data points like funding rounds and market trends to model a company's potential outcomes, similar to how VCs assess investments.
